Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BLS.AX
BuyBLS Pharmaceuticals Limited · Healthcare · Australia · $152M · Avg Vol: $99K/d
79
StockRankGet insider-trade alerts
Q
56
V
32
M
85
P/E (TTM)
23.1x
ROE
66.1%
D/E
0.3x
Dividend %
—
COMPANY DESCRIPTION
BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan.
FINANCIAL SUMMARY (AUD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.4M | 5.2M | 9.3M | — | 96.4% | 48.1M |
| EPS (AUD) | -0.00 | -0.02 | -0.07 | 0.02 | — | 0.04 |
| Shares | 230.3M | 190.2M | 204.7M | 216.5M | -6.0% | 230.3M |
| Debt | — | — | 0.7M | — | — | 5.4M |
| Equity | 1.9M | 15.1M | 3.6M | — | 38.2% | — |
| Op CF | 0.4M | -1.1M | -3.6M | — | — | 2.0M |
| Inv CF | -5.8K | 3.6M | -0.5M | — | — | — |
| Fin CF | — | 0.9M | 1.2M | — | — | — |
Loading 1Y...
PRICE (1Y)+3.9%
SMA 50SMA 200
Close
$0.6627
RSI (14)
51.3
52W High
$0.7881
From 52W High
0.8%
SCORE BREAKDOWN
Quality
56
ROIC (ROA)
25.0%*94.7
ROE
66.1%98.3
GP/Assets
—N/A
Op. Margin
31.7%92.1
FCF/Assets
—N/A
Piotroski
29.7
Int. Cover
—89.3
D/E Ratio
0.27x44.3
Current Ratio
2.79x51.2
Value
32
P/E (TTM)
23.1x52.2
EV/EBITDA
20.1x31.8
P/FCF
—N/A
P/B
10.2x11.6
P/S
4.4x45.9
Div Yield
—N/A
Momentum
85
52W High %
84%72.1
RS 6M
56%91.9
SMA 50/200
1.41x96.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
124%86.2
FUNDAMENTALS
Market Cap
$152M
P/E (Forward)
—
Gross Margin
41.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLS.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLS.AX | BLS Pharmaceuticals Limited(you) | $152M | 79 | Buy |
| CUVL | Clinuvel Pharmaceuticals Limited | $311M | 87 | Strong Buy |
| ATHE | Alterity Therapeutics Limited | $82M | 55 | Hold |
| SPL.AX | Starpharma Holdings Limited | $244M | 49 | Hold |
| KZIA | Kazia Therapeutics Limited | $155M | 36 | Hold |
| AVE.AX | Avecho Biotechnology Limited | $64M | 42 | Hold |
| NEU.AX | Neuren Pharmaceuticals Limited | $1.9B | 74 | Buy |
| TTX.AX | Tetratherix Limited | $263M | 34 | Sell |
| OCC.AX | Orthocell Limited | $147M | 14 | Strong Sell |
| ACW.AX | Actinogen Medical Limited | $118M | 18 | Strong Sell |
Peer medians: ROE -25.5% · P/E 35.3x · Gross margin 62.6%